Belgian Cancer Registry

CANCER FACT SHEET 2024
GASTRIC CANCER
ICD-10 C16.1-C16.9

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

GIST: Gastrointestinal stromal tumour

ADC: Adenocarcinoma

NENs: Neuroendocrine neoplasms

Cardia of stomach: is defined as C16.0 by ICD-10, and included in the Cancer Fact Sheet of oesophageal cancer

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Gastric cancer incidence: by region 5

1.1.1. Gastric cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Gastric cancer incidence: by tumour stage 7

1.2.1. Gastric cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Gastric cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Gastric cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3. Gastric cancer incidence: by tumour type 9

1.3.1. Gastric cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.4. Gastric cancer incidence: by tumour type and tumour stage 10

1.4.1. Gastric cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 10

2. CANCER INCIDENCE TRENDS 11

2.1. Gastric cancer incidence trends: by region 11

2.1.1. Gastric cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

2.1.2. Gastric cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.2. Gastric cancer incidence trends: by tumour stage 13

2.2.1. Gastric cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 13

2.3. Gastric cancer incidence trends: by tumour type 15

2.3.1. Gastric cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 15

2.4. Gastric cancer incidence trends: by age group 16

2.4.1. Gastric cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.4.2. Gastric cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

3. CANCER PREVALENCE 18

3.1. Gastric cancer prevalence: by region 18

3.1.1. Gastric cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 18

4. CANCER SURVIVAL 19

4.1. Gastric cancer survival: by region 19

4.1.1. Gastric cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 19
4.2. Gastric cancer survival: by tumour stage 21
4.2.1. Gastric cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 21
4.2.2. Gastric cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024 22
4.2.3. Gastric cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024 23
4.3. Gastric cancer survival: by tumour type and tumour stage 24
4.3.1. Gastric cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024 .. 24
5. CANCER SURVIVAL TRENDS 26
5.1. Gastric cancer survival trends: by tumour stage 26
5.1.1. Gastric cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-202426
5.2. Gastric cancer survival trends: by tumour type and tumour stage 28
5.2.1. Gastric cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024 28
6. CANCER MORTALITY 32
6.1. Gastric cancer mortality: by region 32
6.1.1. Gastric cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 32
7. CANCER MORTALITY TRENDS 34
7.1. Gastric cancer mortality trends: by region 34
7.1.1. Gastric cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 34
7.1.2. Gastric cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 35

1.1. Gastric cancer incidence: by region

1.1.1. Gastric cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	1	3	2	8	11	19	21	38	61	55	64	81	70	47	17	5	503	9.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[0.5]	[2.1]	[2.9]	[5.1]	[5.3]	[9.5]	[16.1]	[16.9]	[23.8]	[38.0]	[55.3]	[57.2]	[52.2]	[78.4]	[8.7]	(8.4; 10.0)
Brussels	0	0	0	0	1	1	0	2	1	6	7	6	9	6	5	5	7	3	1	1	61	14.0
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[1.9]	[0.0]	[4.2]	[2.2]	[13.6]	[17.0]	[16.6]	[30.5]	[27.6]	[29.4]	[38.8]	[85.1]	[59.2]	[44.5]	[177.6]	[10.0]	(10.4; 17.7)
Flanders	0	0	0	0	0	0	1	5	7	10	10	23	35	33	43	51	42	33	13	3	309	9.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[2.3]	[3.1]	[4.7]	[4.4]	[9.6]	[15.1]	[16.4]	[25.9]	[37.8]	[50.1]	[59.3]	[59.4]	[71.3]	[9.1]	(8.0; 10.1)
Wallonia	0	0	0	0	0	2	1	1	3	3	4	9	17	16	16	25	21	11	3	1	133	8.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.8]	[0.8]	[2.6]	[2.6]	[3.2]	[7.3]	[14.4]	[15.6]	[18.7]	[38.4]	[60.8]	[51.3]	[35.4]	[62.3]	[7.4]	(6.8; 9.6)
Females																						
Belgium	0	0	0	0	0	1	3	15	18	17	26	40	42	48	50	53	36	46	18	8	421	6.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[3.9]	[4.7]	[4.6]	[6.7]	[10.2]	[10.9]	[13.9]	[16.7]	[20.7]	[20.7]	[33.9]	[25.0]	[37.0]	[7.1]	(5.9; 7.1)
Brussels	0	0	0	0	0	0	0	4	3	3	3	5	5	5	4	1	2	5	0	0	40	7.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[8.2]	[6.6]	[7.2]	[7.8]	[14.5]	[16.4]	[19.9]	[18.6]	[5.4]	[15.6]	[51.8]	[0.0]	[0.0]	[6.3]	(5.1; 9.7)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	1	9	8	9	15	20	22	28	28	29	23	30	11	6	239	6.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[4.2]	[3.6]	[4.3]	[6.8]	[8.6]	[9.5]	[13.5]	[15.8]	[18.7]	[21.0]	[34.6]	[24.3]	[46.6]	[6.9]	(5.3; 6.9)
Wallonia	0	0	0	0	0	1	2	2	7	5	8	15	15	15	18	23	11	11	7	2	142	7.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.7]	[1.7]	[5.9]	[4.3]	[6.4]	[12.0]	[12.1]	[13.3]	[18.0]	[27.8]	[21.4]	[28.1]	[33.2]	[30.1]	[7.5]	(5.8; 8.1)

1.2. Gastric cancer incidence: by tumour stage

1.2.1. Gastric cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	16 [0.5]	20 [2.1]	29 [6.3]	65 [1.1]	1.2 (0.9; 1.5)	25 [0.7]	26 [2.5]	32 [4.9]	83 [1.4]	1.3 (1.0; 1.6)
II	11 [0.3]	23 [2.4]	39 [8.5]	73 [1.3]	1.4 (1.1; 1.7)	7 [0.2]	11 [1.1]	23 [3.5]	41 [0.7]	0.6 (0.4; 0.8)
III	7 [0.2]	25 [2.6]	22 [4.8]	54 [0.9]	1.0 (0.7; 1.2)	4 [0.1]	4 [0.4]	11 [1.7]	19 [0.3]	0.3 (0.1; 0.4)
IV	22 [0.7]	51 [5.2]	66 [14.3]	139 [2.4]	2.6 (2.1; 3.0)	37 [1.1]	31 [3.0]	40 [6.1]	108 [1.8]	1.7 (1.4; 2.0)
X/NA	13 [0.4]	13 [1.3]	38 [8.2]	64 [1.1]	1.2 (0.9; 1.5)	11 [0.3]	17 [1.7]	21 [3.2]	49 [0.8]	0.7 (0.5; 0.9)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.2. Gastric cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	21 [0.6]	18 [1.8]	27 [5.9]	66 [1.1]	1.2 (0.9; 1.5)	10 [0.3]	27 [2.6]	21 [3.2]	58 [1.0]	0.9 (0.7; 1.1)
II	7 [0.2]	21 [2.2]	21 [4.6]	49 [0.8]	0.9 (0.6; 1.1)	9 [0.3]	6 [0.6]	14 [2.1]	29 [0.5]	0.4 (0.3; 0.6)
III	5 [0.1]	9 [0.9]	15 [3.3]	29 [0.5]	0.5 (0.3; 0.7)	8 [0.2]	7 [0.7]	7 [1.1]	22 [0.4]	0.3 (0.2; 0.5)
IV	4 [0.1]	12 [1.2]	11 [2.4]	27 [0.5]	0.5 (0.3; 0.7)	13 [0.4]	7 [0.7]	6 [0.9]	26 [0.4]	0.4 (0.3; 0.6)
X/NA	32 [0.9]	72 [7.4]	120 [26.1]	224 [3.9]	4.2 (3.7; 4.8)	44 [1.3]	42 [4.1]	79 [12.0]	165 [2.8]	2.4 (2.1; 2.8)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.3. Gastric cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	21 [0.6]	23 [2.4]	36 [7.8]	80 [1.4]	1.5 (1.1; 1.8)	26 [0.8]	33 [3.2]	28 [4.2]	87 [1.5]	1.4 (1.1; 1.7)
II	11 [0.3]	23 [2.4]	40 [8.7]	74 [1.3]	1.4 (1.1; 1.7)	7 [0.2]	13 [1.3]	26 [3.9]	46 [0.8]	0.7 (0.5; 0.9)
III	9 [0.3]	26 [2.7]	25 [5.4]	60 [1.0]	1.1 (0.8; 1.3)	6 [0.2]	5 [0.5]	16 [2.4]	27 [0.5]	0.4 (0.2; 0.5)
IV	21 [0.6]	51 [5.2]	68 [14.8]	140 [2.4]	2.6 (2.2; 3.0)	37 [1.1]	31 [3.0]	40 [6.1]	108 [1.8]	1.7 (1.4; 2.0)
X/NA	7 [0.2]	9 [0.9]	25 [5.4]	41 [0.7]	0.8 (0.5; 1.0)	8 [0.2]	7 [0.7]	17 [2.6]	32 [0.5]	0.4 (0.3; 0.6)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.3. Gastric cancer incidence: by tumour type

1.3.1. Gastric cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
GIST	34 [1.0]	48 [4.9]	26 [5.6]	108 [1.9]	1.9 (1.5; 2.3)	36 [1.1]	51 [5.0]	34 [5.2]	121 [2.0]	1.9 (1.6; 2.3)
ADC	48 [1.4]	116 [11.9]	176 [38.2]	340 [5.9]	6.3 (5.6; 7.0)	65 [1.9]	59 [5.7]	110 [16.7]	234 [3.9]	3.5 (3.1; 4.0)
NENs	17 [0.5]	10 [1.0]	14 [3.0]	41 [0.7]	0.8 (0.5; 1.0)	16 [0.5]	27 [2.6]	10 [1.5]	53 [0.9]	0.9 (0.6; 1.1)
Other	4 [0.1]	6 [0.6]	4 [0.9]	14 [0.2]	0.3 (0.1; 0.4)	3 [0.1]	3 [0.3]	7 [1.1]	13 [0.2]	0.2 (0.1; 0.3)

1.4. Gastric cancer incidence: by tumour type and tumour stage

1.4.1. Gastric cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
ADC	**I**	8 [0.2]	17 [1.7]	28 [6.1]	53 [0.9]	1.0 (0.7; 1.2)	14 [0.4]	16 [1.6]	19 [2.9]	49 [0.8]	0.8 (0.5; 1.0)
	II	9 [0.3]	20 [2.1]	36 [7.8]	65 [1.1]	1.2 (0.9; 1.5)	7 [0.2]	9 [0.9]	24 [3.6]	40 [0.7]	0.6 (0.4; 0.8)
	III	9 [0.3]	26 [2.7]	25 [5.4]	60 [1.0]	1.1 (0.8; 1.3)	4 [0.1]	5 [0.5]	15 [2.3]	24 [0.4]	0.3 (0.2; 0.5)
	IV	20 [0.6]	49 [5.0]	65 [14.1]	134 [2.3]	2.5 (2.1; 2.9)	37 [1.1]	28 [2.7]	38 [5.8]	103 [1.7]	1.6 (1.3; 1.9)
	X/NA	2 [0.1]	4 [0.4]	22 [4.8]	28 [0.5]	0.6 (0.3; 0.8)	3 [0.1]	1 [0.1]	14 [2.1]	18 [0.3]	0.2 (0.1; 0.3)
NENs	**I**	13 [0.4]	6 [0.6]	8 [1.7]	27 [0.5]	0.5 (0.3; 0.7)	12 [0.4]	17 [1.7]	7 [1.1]	36 [0.6]	0.6 (0.4; 0.8)
	II	1 [0.0]	1 [0.1]	3 [0.7]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	4 [0.4]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.1)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	2 [0.1]	0 [0.0]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
	IV	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)
	X/NA	3 [0.1]	3 [0.3]	2 [0.4]	8 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	5 [0.5]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
Other	**I**	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
	II	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	2 [0.2]	2 [0.4]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	2 [0.2]	1 [0.2]	3 [0.1]	0.0 (0.0; 0.1)
	X/NA	2 [0.1]	2 [0.2]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)	3 [0.1]	1 [0.1]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)

Note: Excluding gastrointestinal stromal tumours (GIST)

2.1. Gastric cancer incidence trends: by region

2.1.1. Gastric cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	663	665	640	622	612	573	564	631	615	593	538	525	559	538	567	544	486	507	516	487	503		
	CR	13.0	13.0	12.4	12.0	11.7	10.9	10.6	11.7	11.4	10.9	9.8	9.5	10.1	9.7	10.1	9.7	8.6	8.9	9.0	8.5	8.7		
	ESR2013	17.8	17.5	17.1	15.3	15.2	14.2	13.3	14.6	14.1	13.4	11.6	11.2	11.6	11.2	11.5	10.8	9.5	9.8	9.7	9.1	9.2	-3.4 (-3.7; -3.0)	2004-2024
Brussels	**N**	55	57	59	60	53	42	50	63	54	49	55	48	57	46	52	59	48	46	42	46	61		
	CR	11.5	11.8	12.0	12.1	10.5	8.1	9.5	11.6	9.8	8.7	9.7	8.4	9.8	7.9	8.9	10.0	8.0	7.7	7.0	7.6	10.0		
	ESR2013	16.9	16.9	18.8	16.9	15.6	12.4	14.2	18.8	15.4	14.0	15.6	13.1	14.5	11.6	13.0	14.8	12.4	11.6	9.3	11.3	14.0	-2.1 (-3.0; -1.2)	2004-2024
Flanders	**N**	399	416	393	389	397	369	367	383	373	386	348	325	323	321	361	309	306	310	301	289	309		
	CR	13.4	14.0	13.1	12.9	13.1	12.0	11.9	12.3	11.9	12.2	11.0	10.2	10.1	10.0	11.1	9.5	9.3	9.4	9.1	8.6	9.1		
	ESR2013	17.8	18.4	17.1	15.9	16.2	15.2	14.2	14.1	14.0	14.3	12.3	11.2	10.9	10.9	11.8	9.9	9.6	9.5	9.1	8.6	9.1	-3.8 (-4.1; -3.4)	2004-2024
Wallonia	**N**	209	192	188	173	162	162	147	185	188	158	135	152	179	171	154	176	132	151	173	152	133		
	CR	12.7	11.7	11.3	10.4	9.7	9.6	8.6	10.8	10.9	9.1	7.7	8.7	10.2	9.7	8.7	9.9	7.4	8.5	9.7	8.4	7.4		
	ESR2013	18.0	15.8	16.7	13.7	13.2	12.8	11.2	14.5	14.0	11.4	9.1	10.5	12.1	11.7	10.1	11.7	8.4	9.7	10.9	9.2	8.2	-3.0 (-3.8; -2.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Gastric cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	462	456	489	435	481	477	475	477	443	443	475	433	457	394	447	423	352	428	421	420	421		
	CR	8.7	8.5	9.1	8.1	8.8	8.7	8.6	8.5	7.9	7.8	8.4	7.6	8.0	6.8	7.7	7.3	6.0	7.3	7.2	7.1	7.1		
	ESR2013	8.7	8.4	8.8	7.9	8.5	8.4	8.1	8.1	7.4	7.4	8.0	7.1	7.5	6.4	7.2	6.7	5.6	6.9	6.6	6.6	6.5	-1.7 (-2.2; -1.3)	2004-2024
Brussels	**N**	30	36	29	37	57	51	48	37	38	43	51	35	53	46	66	45	52	49	43	44	40		
	CR	5.8	6.9	5.5	6.9	10.5	9.2	8.5	6.4	6.5	7.3	8.5	5.8	8.7	7.6	10.8	7.3	8.4	7.9	6.9	7.0	6.3		
	ESR2013	5.9	7.4	5.5	7.4	12.3	9.8	9.6	7.0	7.0	8.8	10.1	7.0	10.5	9.3	12.9	8.6	10.1	9.5	8.2	8.5	7.4	1.1 (-0.5; 2.7)	2004-2024
																							3.3 (0.1; 6.5)	2004-2015
																							-1.5 (-5.3; 2.4)	2016-2024
Flanders	**N**	302	297	311	271	280	306	291	279	280	261	282	273	259	232	232	253	200	247	243	234	239		
	CR	9.9	9.7	10.1	8.7	9.0	9.7	9.2	8.7	8.7	8.1	8.7	8.4	7.9	7.0	7.0	7.6	6.0	7.4	7.2	6.8	6.9		
	ESR2013	9.8	9.6	9.8	8.5	8.4	9.2	8.5	8.1	7.9	7.4	8.0	7.4	7.0	6.2	6.2	6.6	5.2	6.5	6.3	6.0	6.1	-2.7 (-3.2; -2.2)	2004-2024
Wallonia	**N**	130	123	149	127	144	120	136	161	125	139	142	125	145	116	149	125	100	132	135	142	142		
	CR	7.5	7.0	8.5	7.2	8.1	6.7	7.6	8.9	6.9	7.6	7.7	6.8	7.9	6.3	8.0	6.7	5.4	7.1	7.2	7.6	7.5		
	ESR2013	7.6	6.8	8.2	7.2	8.0	6.6	7.3	8.7	6.5	7.2	7.5	6.6	7.5	6.0	7.7	6.3	5.0	6.8	6.8	7.0	7.0	-0.8 (-1.6; 0.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Gastric cancer incidence trends: by tumour stage

2.2.1. Gastric cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	77	81	94	82	80			56	79	79	75	87		
	CR	1.4	1.4	1.6	1.4	1.4			1.0	1.4	1.3	1.3	1.5		
	ESR2013	1.5	1.6	1.8	1.5	1.5	-3.4 (-4.5; -2.2)	2004-2024	0.9	1.3	1.2	1.2	1.4	-0.7 (-1.9; 0.7)	2004-2024
														-3.1 (-4.9; -1.3)	2004-2018
														5.4 (0.3; 10.7)	2019-2024
II	**N**	65	60	76	65	74			43	54	63	46	46		
	CR	1.1	1.1	1.3	1.1	1.3			0.7	0.9	1.1	0.8	0.8		
	ESR2013	1.3	1.2	1.4	1.2	1.4	-0.6 (-1.9; 0.8)	2004-2024	0.7	0.8	0.9	0.7	0.7	0.2 (-1.1; 1.5)	2004-2024
							6.8 (2.7; 11.0)	2004-2012						7.1 (2.7; 11.8)	2004-2011
							-5.2 (-7.5; -2.8)	2013-2024						-3.3 (-5.3; -1.3)	2012-2024
III	**N**	58	65	53	67	60			41	36	37	45	27		
	CR	1.0	1.1	0.9	1.2	1.0			0.7	0.6	0.6	0.8	0.5		
	ESR2013	1.1	1.3	1.0	1.3	1.1	-3.2 (-4.4; -2.0)	2004-2024	0.6	0.6	0.6	0.7	0.4	-2.6 (-3.6; -1.6)	2004-2024
														0.2 (-1.7; 2.1)	2004-2016
														-6.6 (-9.3; -3.8)	2017-2024
IV	**N**	158	148	145	123	140			90	115	96	112	108		
	CR	2.8	2.6	2.5	2.1	2.4			1.5	2.0	1.6	1.9	1.8		
	ESR2013	3.0	2.9	2.7	2.3	2.6	-2.0 (-2.7; -1.4)	2004-2024	1.5	1.9	1.5	1.7	1.7	-0.2 (-1.0; 0.6)	2004-2024
							-4.5 (-6.3; -2.8)	2004-2012							
							2.0 (-1.2; 5.4)	2013-2016							

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
							-1.5 (-3.3; 0.4)	2017-2024							
X/NA	N	38	28	39	34	41			42	27	28	22	32		
	CR	0.7	0.5	0.7	0.6	0.7			0.7	0.5	0.5	0.4	0.5		
	ESR2013	0.8	0.5	0.8	0.7	0.8	-11.8 (-13.0; -10.6)	2004-2024	0.6	0.4	0.4	0.3	0.4	-11.3 (-12.5; -10.1)	2004-2024
														-9.3 (-11.3; -7.4)	2004-2017
														-14.9 (-18.6; -11.0)	2018-2024

Note: Excluding gastrointestinal stromal tumours (GIST)

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Gastric cancer incidence trends: by tumour type

2.3.1. Gastric cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Type		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
GIST	**N**	90	125	109	116	108			80	117	118	120	121		
	CR	1.6	2.2	1.9	2.0	1.9			1.4	2.0	2.0	2.0	2.0		
	ESR2013	1.7	2.3	2.0	2.1	1.9	3.2 (2.5; 4.0)	2004-2024	1.3	1.9	2.0	2.0	1.9	5.2 (4.0; 6.3)	2004-2024
							6.0 (4.7; 7.4)	2004-2016						9.6 (6.7; 12.6)	2004-2013
							-0.8 (-2.8; 1.2)	2017-2024						1.6 (-0.5; 3.9)	2014-2024
ADC	**N**	356	335	361	313	340			231	269	246	242	234		
	CR	6.3	5.9	6.3	5.4	5.9			4.0	4.6	4.2	4.1	3.9		
	ESR2013	7.0	6.5	6.9	5.9	6.3	-4.9 (-5.3; -4.5)	2004-2024	3.6	4.2	3.7	3.7	3.5	-3.9 (-4.3; -3.4)	2004-2024
NENs	**N**	26	34	34	42	41			35	37	43	50	53		
	CR	0.5	0.6	0.6	0.7	0.7			0.6	0.6	0.7	0.8	0.9		
	ESR2013	0.5	0.6	0.6	0.8	0.8	3.6 (2.0; 5.2)	2004-2024	0.6	0.6	0.7	0.8	0.9	3.4 (2.2; 4.6)	2004-2024
Other	**N**	14	13	12	16	14			6	5	14	8	13		
	CR	0.2	0.2	0.2	0.3	0.2			0.1	0.1	0.2	0.1	0.2		
	ESR2013	0.3	0.2	0.2	0.3	0.3	-3.2 (-4.8; -1.4)	2004-2024	0.1	0.1	0.2	0.1	0.2	-2.4 (-5.7; 1.0)	2004-2024
							-14.7 (-21.5; -7.3)	2004-2009							
							1.6 (-6.4; 10.4)	2010-2013							
							0.8 (-2.2; 4.0)	2014-2024							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Gastric cancer incidence trends: by age group

2.4.1. Gastric cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	119	140	99	115	103	103	109	118	116	119	96	111	131	123	124	90	83	102	112	104	103		
	CR	3.7	4.4	3.1	3.6	3.2	3.2	3.3	3.6	3.5	3.6	2.9	3.3	3.9	3.7	3.7	2.7	2.5	3.1	3.3	3.1	3.0		
	ESR2013	4.0	4.6	3.2	3.6	3.2	3.2	3.4	3.7	3.5	3.6	2.9	3.3	3.9	3.7	3.7	2.7	2.5	3.0	3.3	3.1	3.1	-1.2 (-2.1; -0.3)	2004-2024
60-74	**N**	264	260	240	234	223	204	194	237	238	223	213	200	196	172	203	217	207	180	196	162	180		
	CR	38.8	38.0	34.9	33.4	31.3	28.1	26.2	31.4	30.9	28.5	26.7	24.6	23.5	20.1	23.1	24.2	22.6	19.3	20.7	16.9	18.5		
	ESR2013	38.5	37.8	34.9	33.8	32.0	29.0	27.3	32.1	32.3	29.9	27.4	26.0	24.3	20.7	23.5	24.5	23.0	19.5	21.2	17.0	18.7	-3.5 (-4.1; -3.0)	2004-2024
75+	**N**	280	265	301	272	285	266	261	276	261	250	229	214	232	243	240	237	196	224	208	221	220		
	CR	95.5	87.5	95.8	83.5	84.6	77.0	73.7	76.4	70.7	66.5	59.7	54.7	58.8	61.6	60.4	58.7	47.4	53.8	48.2	49.6	47.8		
	ESR2013	101.3	95.7	105.3	84.2	88.4	83.7	75.9	79.5	74.9	70.9	60.2	55.6	58.6	63.0	60.8	57.9	47.5	53.1	47.8	49.4	48.2	-3.9 (-4.4; -3.4)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Gastric cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	79	71	103	82	101	88	82	99	78	95	106	90	98	92	113	81	78	114	114	102	120		
	CR	2.5	2.3	3.2	2.6	3.2	2.7	2.5	3.0	2.4	2.9	3.2	2.7	3.0	2.8	3.4	2.5	2.4	3.5	3.5	3.1	3.6		
	ESR2013	2.6	2.3	3.3	2.6	3.2	2.8	2.6	3.1	2.4	2.9	3.2	2.7	3.0	2.8	3.4	2.5	2.4	3.4	3.5	3.1	3.6	0.9 (0.0; 1.9)	2004-2024
60-74	**N**	137	138	125	136	129	140	131	134	120	127	150	122	146	128	140	142	116	151	144	136	140		
	CR	17.7	17.8	16.2	17.4	16.4	17.5	16.2	16.3	14.4	15.0	17.5	14.0	16.4	14.0	14.9	14.8	11.9	15.2	14.3	13.4	13.6		
	ESR2013	17.2	17.3	15.9	17.4	16.4	17.6	16.4	16.4	14.6	15.4	17.8	14.1	16.7	14.2	15.0	14.9	11.9	15.2	14.4	13.4	13.7	-1.3 (-1.8; -0.7)	2004-2024
75+	**N**	246	247	261	217	251	249	262	244	245	221	219	221	213	174	194	200	158	163	163	181	161		
	CR	47.3	46.5	47.9	38.9	44.1	43.1	44.7	41.1	40.8	36.6	35.9	35.8	34.6	28.4	31.7	32.6	25.5	26.3	25.7	28.0	24.4		
	ESR2013	48.1	46.9	47.7	39.2	43.9	43.1	43.7	40.5	39.4	35.4	35.7	35.5	33.4	27.4	30.5	30.9	24.8	26.0	24.8	28.0	23.7	-3.6 (-4.1; -3.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Gastric cancer prevalence: by region

3.1.1. Gastric cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	381	1,323	2,158	2,641	2,971	350	1,206	1,994	2,564	2,902
	CR	6.5	22.7	37.0	45.3	51.0	5.8	20.1	33.3	42.8	48.4
	ESR2013	6.8	23.6	38.5	47.3	53.3	5.5	18.7	30.6	39.0	43.9
Brussels	**N**	51	140	218	259	291	34	126	223	273	304
	CR	8.3	22.8	35.4	42.1	47.3	5.3	19.7	34.8	42.6	47.5
	ESR2013	11.1	31.3	50.0	60.9	68.4	6.3	23.9	42.7	52.3	57.9
Flanders	**N**	231	777	1,247	1,529	1,733	197	678	1,102	1,430	1,641
	CR	6.8	22.9	36.7	45.0	51.0	5.7	19.6	31.8	41.3	47.4
	ESR2013	6.6	22.2	35.7	43.8	49.7	5.1	17.3	27.7	35.6	40.6
Wallonia	**N**	99	406	693	853	947	119	402	669	861	957
	CR	5.5	22.4	38.2	47.0	52.2	6.3	21.3	35.4	45.6	50.6
	ESR2013	5.8	24.0	40.9	50.6	56.3	5.9	19.8	32.6	41.7	46.2

4.1. Gastric cancer survival: by region

4.1.1. Gastric cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	9,325	68.3% (67.3%; 69.3%)	52.4% (51.2%; 53.6%)	48.3% (46.9%; 49.7%)	47.4% (44.5%; 50.5%)
Males						
Belgium	**All ages 15+**	5,180	66.7% (65.3%; 68.1%)	50.1% (48.5%; 51.7%)	45.6% (43.8%; 47.5%)	44.8% (40.9%; 49.1%)
	15-59	1,075	80.1% (77.8%; 82.6%)	62.4% (59.4%; 65.5%)	58.4% (55.3%; 61.6%)	55.2% (51.6%; 59.0%)
	60-74	1,894	72.8% (70.8%; 74.9%)	55.7% (53.3%; 58.2%)	50.5% (47.9%; 53.2%)	47.6% (43.7%; 51.8%)
	75+	2,212	54.9% (52.6%; 57.2%)	39.3% (36.7%; 42.0%)	35.2% (32.1%; 38.6%)	37.0% (28.9%; 47.4%)
Brussels	**All ages 15+**	499	67.6% (63.4%; 72.1%)	53.3% (48.6%; 58.5%)	47.0% (41.8%; 53.0%)	39.7% (31.6%; 50.0%)
	15-59	178	76.1% (70.1%; 82.7%)	59.4% (52.4%; 67.3%)	56.0% (48.7%; 64.4%)	54.9% (46.9%; 64.2%)
	60-74	181	73.8% (67.4%; 80.8%)	59.2% (51.6%; 67.8%)	47.2% (39.0%; 57.1%)	43.1% (31.7%; 58.7%)
	75+	140	48.5% (40.3%; 58.4%)	38.3% (29.5%; 49.7%)	36.4% (26.0%; 51.0%)	16.3% (6.3%; 41.9%)
Flanders	**All ages 15+**	3,123	65.2% (63.5%; 67.0%)	46.8% (44.8%; 48.9%)	43.2% (40.9%; 45.6%)	45.8% (40.5%; 51.7%)
	15-59	550	79.9% (76.6%; 83.3%)	61.2% (57.1%; 65.6%)	57.7% (53.5%; 62.3%)	54.3% (49.6%; 59.6%)
	60-74	1,079	72.2% (69.4%; 75.0%)	53.0% (49.9%; 56.3%)	48.9% (45.5%; 52.5%)	47.5% (43.0%; 52.5%)
	75+	1,494	54.8% (52.1%; 57.7%)	37.0% (33.9%; 40.2%)	33.6% (30.0%; 37.6%)	40.8% (30.1%; 55.2%)
Wallonia	**All ages 15+**	1,558	69.3% (66.9%; 71.8%)	55.6% (52.8%; 58.6%)	50.0% (46.6%; 53.7%)	43.9% (37.1%; 51.9%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	347	82.6% (78.7%; 86.8%)	65.8% (60.8%; 71.2%)	60.7% (55.4%; 66.6%)	56.8% (50.5%; 64.0%)
	60-74	634	73.7% (70.2%; 77.4%)	59.3% (55.2%; 63.7%)	54.1% (49.5%; 59.0%)	48.9% (41.4%; 57.8%)
	75+	578	56.4% (52.1%; 61.1%)	45.1% (40.1%; 50.8%)	39.0% (32.5%; 46.9%)	31.5% (19.6%; 50.7%)
Females						
Belgium	**All ages 15+**	4,145	70.4% (68.9%; 71.8%)	55.3% (53.5%; 57.1%)	51.5% (49.5%; 53.6%)	50.6% (46.5%; 55.1%)
	15-59	990	85.4% (83.2%; 87.7%)	67.8% (64.8%; 70.9%)	62.6% (59.5%; 66.0%)	60.3% (56.7%; 64.2%)
	60-74	1,344	77.3% (75.1%; 79.7%)	63.9% (61.2%; 66.7%)	59.8% (56.8%; 62.9%)	54.0% (49.6%; 58.8%)
	75+	1,812	57.0% (54.6%; 59.6%)	42.1% (39.3%; 45.1%)	39.3% (36.0%; 43.0%)	41.9% (33.9%; 51.7%)
Brussels	**All ages 15+**	459	73.1% (68.9%; 77.5%)	57.5% (52.6%; 63.0%)	53.3% (47.7%; 59.5%)	63.5% (54.9%; 73.5%)
	15-59	157	86.1% (80.8%; 91.7%)	70.0% (63.0%; 77.9%)	62.9% (55.2%; 71.6%)	60.0% (51.7%; 69.6%)
	60-74	150	75.3% (68.5%; 82.7%)	61.1% (53.2%; 70.1%)	56.8% (48.3%; 66.8%)	57.2% (46.4%; 70.6%)
	75+	152	56.9% (49.0%; 66.0%)	41.2% (32.5%; 52.3%)	39.7% (29.2%; 54.0%)	63.4% (42.3%; 94.9%)
Flanders	**All ages 15+**	2,389	69.3% (67.4%; 71.3%)	53.7% (51.4%; 56.0%)	49.7% (47.1%; 52.5%)	46.6% (41.0%; 52.9%)
	15-59	507	84.2% (81.0%; 87.4%)	65.6% (61.5%; 70.0%)	61.0% (56.6%; 65.7%)	58.5% (53.4%; 64.0%)
	60-74	724	76.8% (73.7%; 80.0%)	62.0% (58.3%; 65.8%)	57.0% (53.0%; 61.2%)	48.2% (41.6%; 55.8%)
	75+	1,159	58.2% (55.1%; 61.4%)	43.3% (39.9%; 47.1%)	39.9% (35.8%; 44.5%)	38.8% (29.8%; 50.5%)
Wallonia	**All ages 15+**	1,297	71.3% (68.7%; 74.0%)	57.5% (54.4%; 60.7%)	54.2% (50.8%; 57.9%)	53.3% (47.0%; 60.5%)
	15-59	326	87.0% (83.4%; 90.8%)	70.2% (65.2%; 75.6%)	65.2% (59.7%; 71.1%)	63.3% (57.2%; 70.1%)
	60-74	470	78.8% (75.1%; 82.7%)	67.7% (63.3%; 72.5%)	64.9% (60.0%; 70.2%)	60.6% (53.9%; 68.1%)
	75+	501	54.1% (49.6%; 59.1%)	39.4% (34.2%; 45.3%)	37.2% (31.1%; 44.5%)	38.8% (25.0%; 60.3%)

4.2. Gastric cancer survival: by tumour stage

4.2.1. Gastric cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	7,246	59.9% (58.7%; 61.1%)	46.4% (45.2%; 47.7%)	40.3% (39.0%; 41.6%)	36.8% (35.5%; 38.2%)	35.3% (33.9%; 36.8%)	31.3% (28.3%; 34.6%)
Males							
All	4,140	59.0% (57.4%; 60.6%)	45.0% (43.4%; 46.7%)	39.3% (37.6%; 41.1%)	35.9% (34.2%; 37.8%)	34.1% (32.2%; 36.1%)	27.5% (23.7%; 32.0%)
I	638	86.1% (83.0%; 89.4%)	79.0% (75.1%; 83.1%)	74.9% (70.4%; 79.6%)	72.8% (67.7%; 78.2%)	70.2% (64.1%; 76.9%)	61.9% (46.4%; 82.5%)
II	718	71.4% (67.9%; 75.1%)	56.2% (52.2%; 60.4%)	50.9% (46.7%; 55.4%)	46.7% (42.3%; 51.6%)	43.8% (39.0%; 49.1%)	39.9% (31.9%; 49.9%)
III	460	72.0% (67.7%; 76.5%)	58.3% (53.5%; 63.5%)	50.5% (45.5%; 56.1%)	44.4% (39.1%; 50.4%)	39.8% (34.0%; 46.5%)	35.1% (25.9%; 47.7%)
IV	1,357	33.8% (31.3%; 36.5%)	15.9% (13.9%; 18.1%)	9.4% (7.8%; 11.3%)	6.6% (5.1%; 8.5%)	5.6% (4.2%; 7.5%)	4.0% (2.5%; 6.4%)
X/NA	970	60.9% (57.7%; 64.3%)	48.6% (45.1%; 52.3%)	43.5% (39.9%; 47.5%)	40.2% (36.5%; 44.4%)	39.5% (35.5%; 43.9%)	27.5% (21.0%; 36.0%)
Females							
All	3,106	61.0% (59.3%; 62.9%)	48.3% (46.4%; 50.2%)	41.5% (39.5%; 43.5%)	38.0% (36.0%; 40.1%)	37.0% (34.8%; 39.3%)	36.2% (31.7%; 41.2%)
I	546	88.3% (85.2%; 91.5%)	80.5% (76.5%; 84.7%)	78.0% (73.4%; 82.9%)	75.2% (70.2%; 80.6%)	73.1% (67.4%; 79.3%)	69.7% (56.1%; 86.7%)
II	488	70.1% (65.9%; 74.6%)	54.8% (50.1%; 59.9%)	45.0% (40.2%; 50.4%)	40.8% (35.7%; 46.6%)	40.1% (34.7%; 46.4%)	31.7% (24.2%; 41.6%)
III	283	66.8% (61.3%; 72.8%)	50.8% (44.9%; 57.5%)	40.6% (34.7%; 47.6%)	32.9% (27.0%; 40.0%)	32.2% (26.2%; 39.6%)	32.2% (24.9%; 41.6%)
IV	910	33.3% (30.3%; 36.6%)	16.3% (14.0%; 19.0%)	9.2% (7.4%; 11.5%)	7.1% (5.4%; 9.2%)	5.8% (4.3%; 8.0%)	4.8% (2.1%; 11.0%)
X/NA	883	65.9% (62.6%; 69.4%)	56.9% (53.3%; 60.7%)	50.6% (46.8%; 54.7%)	47.0% (43.0%; 51.4%)	46.4% (42.1%; 51.0%)	49.3% (40.8%; 59.7%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.2.2. Gastric cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	7,246	59.9% (58.7%; 61.1%)	46.4% (45.2%; 47.7%)	40.3% (39.0%; 41.6%)	36.8% (35.5%; 38.2%)	35.3% (33.9%; 36.8%)	31.3% (28.3%; 34.6%)
Males							
All	4,140	59.0% (57.4%; 60.6%)	45.0% (43.4%; 46.7%)	39.3% (37.6%; 41.1%)	35.9% (34.2%; 37.8%)	34.1% (32.2%; 36.1%)	27.5% (23.7%; 32.0%)
I	704	94.5% (92.2%; 96.8%)	92.1% (89.1%; 95.2%)	90.6% (87.0%; 94.3%)	87.9% (83.5%; 92.6%)	86.1% (80.7%; 91.9%)	73.9% (62.1%; 87.9%)
II	510	88.8% (85.7%; 92.1%)	77.9% (73.6%; 82.4%)	71.7% (66.8%; 76.9%)	67.7% (62.3%; 73.7%)	63.3% (57.0%; 70.2%)	49.5% (38.3%; 63.9%)
III	514	74.9% (71.0%; 79.1%)	52.1% (47.5%; 57.0%)	40.3% (35.8%; 45.4%)	30.5% (26.0%; 35.7%)	24.8% (20.4%; 30.2%)	18.8% (13.5%; 26.3%)
IV	391	37.7% (33.1%; 42.9%)	16.1% (12.8%; 20.4%)	7.3% (5.0%; 10.7%)	4.3% (2.5%; 7.3%)	3.3% (1.8%; 6.2%)	3.5% (1.8%; 6.8%)
X/NA	2,023	39.1% (36.9%; 41.4%)	24.0% (22.0%; 26.1%)	19.0% (17.1%; 21.2%)	17.1% (15.2%; 19.3%)	16.8% (14.7%; 19.1%)	12.5% (8.0%; 19.3%)
Females							
All	3,106	61.0% (59.3%; 62.9%)	48.3% (46.4%; 50.2%)	41.5% (39.5%; 43.5%)	38.0% (36.0%; 40.1%)	37.0% (34.8%; 39.3%)	36.2% (31.7%; 41.2%)
I	558	97.4% (95.4%; 99.4%)	96.6% (93.9%; 99.3%)	95.4% (92.0%; 99.0%)	94.1% (89.9%; 98.5%)	94.4% (89.4%; 99.8%)	87.1% (69.3%; 109.4%)
II	337	90.9% (87.5%; 94.5%)	79.7% (74.9%; 84.9%)	73.3% (67.8%; 79.3%)	69.0% (62.9%; 75.7%)	67.1% (60.5%; 74.4%)	74.2% (61.1%; 90.1%)
III	346	72.2% (67.4%; 77.3%)	53.5% (48.1%; 59.4%)	36.6% (31.3%; 42.7%)	25.4% (20.4%; 31.7%)	25.0% (19.9%; 31.5%)	14.4% (9.0%; 23.1%)
IV	329	45.8% (40.7%; 51.6%)	20.3% (16.3%; 25.3%)	13.2% (9.8%; 17.7%)	9.3% (6.4%; 13.4%)	7.4% (4.8%; 11.4%)	4.8% (2.4%; 9.3%)
X/NA	1,540	42.1% (39.6%; 44.8%)	28.7% (26.3%; 31.3%)	22.0% (19.7%; 24.6%)	19.6% (17.3%; 22.3%)	18.3% (15.9%; 21.0%)	19.6% (15.8%; 24.5%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.2.3. Gastric cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024

Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,246	59.9% (58.7%; 61.1%)	46.4% (45.2%; 47.7%)	40.3% (39.0%; 41.6%)	36.8% (35.5%; 38.2%)	35.3% (33.9%; 36.8%)	31.3% (28.3%; 34.6%)
Males							
All	4,140	59.0% (57.4%; 60.6%)	45.0% (43.4%; 46.7%)	39.3% (37.6%; 41.1%)	35.9% (34.2%; 37.8%)	34.1% (32.2%; 36.1%)	27.5% (23.7%; 32.0%)
I	801	89.4% (86.8%; 92.0%)	84.6% (81.3%; 88.0%)	81.5% (77.6%; 85.5%)	79.3% (74.8%; 84.0%)	78.2% (72.8%; 83.9%)	62.3% (48.9%; 79.3%)
II	752	74.5% (71.2%; 78.0%)	62.0% (58.1%; 66.1%)	56.2% (52.1%; 60.6%)	52.8% (48.4%; 57.6%)	49.5% (44.7%; 55.0%)	40.9% (32.9%; 50.9%)
III	656	71.3% (67.7%; 75.1%)	52.0% (47.9%; 56.4%)	43.5% (39.3%; 48.1%)	36.0% (31.7%; 40.9%)	32.1% (27.7%; 37.2%)	26.1% (19.5%; 35.0%)
IV	1,437	33.9% (31.5%; 36.5%)	15.7% (13.9%; 17.9%)	9.3% (7.7%; 11.1%)	6.6% (5.2%; 8.4%)	5.6% (4.2%; 7.3%)	4.3% (2.8%; 6.6%)
X/NA	498	42.7% (38.2%; 47.6%)	30.5% (26.2%; 35.4%)	26.6% (22.3%; 31.7%)	24.4% (20.1%; 29.7%)	23.6% (19.2%; 29.1%)	17.9% (10.6%; 30.1%)
Females							
All	3,106	61.0% (59.3%; 62.9%)	48.3% (46.4%; 50.2%)	41.5% (39.5%; 43.5%)	38.0% (36.0%; 40.1%)	37.0% (34.8%; 39.3%)	36.2% (31.7%; 41.2%)
I	696	90.4% (87.8%; 93.0%)	86.6% (83.3%; 90.0%)	84.5% (80.6%; 88.6%)	83.3% (78.9%; 87.9%)	82.5% (77.4%; 87.9%)	78.1% (62.7%; 97.3%)
II	517	76.3% (72.4%; 80.4%)	61.7% (57.1%; 66.6%)	53.2% (48.4%; 58.5%)	49.3% (44.2%; 55.0%)	47.9% (42.5%; 53.8%)	52.5% (43.3%; 63.6%)
III	438	68.3% (63.9%; 73.1%)	51.0% (46.2%; 56.3%)	38.8% (34.0%; 44.4%)	29.6% (24.7%; 35.4%)	29.9% (24.9%; 35.9%)	20.5% (13.9%; 30.2%)
IV	964	33.4% (30.4%; 36.5%)	16.3% (14.0%; 18.9%)	9.5% (7.6%; 11.7%)	7.1% (5.5%; 9.2%)	5.7% (4.2%; 7.8%)	4.9% (2.4%; 10.1%)
X/NA	494	51.1% (46.6%; 56.1%)	40.3% (35.8%; 45.5%)	33.4% (28.8%; 38.7%)	30.0% (25.4%; 35.5%)	28.7% (24.0%; 34.4%)	29.6% (23.3%; 37.7%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.3. Gastric cancer survival: by tumour type and tumour stage

4.3.1. Gastric cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		9,325	68.3% (67.3%; 69.3%)	57.6% (56.4%; 58.7%)	52.4% (51.2%; 53.6%)	49.5% (48.2%; 50.8%)	48.3% (46.9%; 49.7%)	47.4% (44.5%; 50.5%)
Males								
GIST	All	1,067	96.9% (95.5%; 98.4%)	94.1% (92.0%; 96.3%)	91.9% (89.3%; 94.6%)	91.1% (88.0%; 94.2%)	90.6% (87.0%; 94.3%)	109.9% (100.8%; 119.7%)
ADC	All	3,693	57.0% (55.3%; 58.7%)	41.9% (40.1%; 43.6%)	36.0% (34.2%; 37.8%)	32.5% (30.7%; 34.5%)	30.3% (28.4%; 32.4%)	24.4% (20.7%; 28.7%)
	I	642	87.2% (84.1%; 90.4%)	81.7% (77.8%; 85.8%)	78.3% (73.8%; 83.0%)	75.9% (70.8%; 81.5%)	73.9% (67.9%; 80.5%)	57.3% (43.1%; 76.1%)
	II	688	74.3% (70.8%; 78.0%)	61.3% (57.3%; 65.6%)	55.0% (50.7%; 59.7%)	51.5% (46.9%; 56.5%)	47.9% (42.8%; 53.6%)	39.5% (31.2%; 50.1%)
	III	640	70.9% (67.2%; 74.8%)	51.0% (46.9%; 55.5%)	42.8% (38.5%; 47.4%)	35.3% (31.0%; 40.2%)	31.4% (26.9%; 36.5%)	25.0% (18.4%; 33.9%)
	IV	1,351	34.5% (31.9%; 37.2%)	15.7% (13.8%; 17.9%)	9.3% (7.7%; 11.2%)	6.5% (5.0%; 8.3%)	5.4% (4.0%; 7.2%)	4.0% (2.5%; 6.4%)
	X/NA	372	30.5% (25.8%; 35.9%)	15.6% (11.8%; 20.4%)	11.7% (8.4%; 16.3%)	9.6% (6.5%; 14.2%)	8.5% (5.5%; 13.1%)	7.8% (4.4%; 14.0%)
NENs	All	326	88.9% (85.2%; 92.8%)	84.3% (79.7%; 89.1%)	80.8% (75.6%; 86.3%)	78.4% (72.6%; 84.6%)	80.2% (74.1%; 86.9%)	63.4% (41.6%; 96.7%)
	I	147	98.7% (95.6%; 101.8%)	97.2% (92.6%; 101.9%)	95.4% (89.6%; 101.6%)	93.8% (86.8%; 101.4%)	97.0% (89.7%; 104.8%)	82.5% (57.6%; 118.2%)
	II	47	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	39	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	83	90.5% (83.6%; 98.1%)	85.3% (76.7%; 94.9%)	85.0% (75.4%; 95.9%)	80.4% (69.1%; 93.6%)	81.5% (69.2%; 96.1%)	53.1% (24.7%; 114.2%)
Other	All	124	39.6% (31.5%; 49.7%)	34.7% (26.6%; 45.3%)	29.3% (20.7%; 41.5%)	27.9% (19.2%; 40.5%)	27.8% (18.7%; 41.2%)	21.1% (9.7%; 45.7%)
	I	12	N<50	N<50	N<50	N<50	N<50	N<50
	II	17	N<50	N<50	N<50	N<50	N<50	N<50
	III	5	N<50	N<50	N<50	N<50	N<50	N<50
	IV	47	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Females								
GIST	All	1,063	98.1% (96.9%; 99.4%)	97.6% (96.0%; 99.3%)	96.4% (94.2%; 98.5%)	94.7% (91.9%; 97.7%)	95.1% (91.8%; 98.5%)	94.8% (87.2%; 103.1%)
ADC	All	2,618	56.9% (54.9%; 58.9%)	42.2% (40.2%; 44.3%)	34.5% (32.4%; 36.6%)	30.6% (28.5%; 32.8%)	29.1% (26.9%; 31.5%)	28.5% (23.9%; 34.0%)
	I	472	87.2% (83.6%; 90.8%)	82.1% (77.7%; 86.7%)	78.3% (73.2%; 83.8%)	76.6% (70.9%; 82.8%)	74.0% (67.4%; 81.2%)	69.0% (51.6%; 92.2%)
	II	473	75.6% (71.5%; 79.9%)	60.2% (55.4%; 65.3%)	50.8% (45.8%; 56.3%)	47.2% (42.0%; 53.0%)	45.3% (39.9%; 51.4%)	49.4% (39.9%; 61.2%)
	III	418	68.7% (64.1%; 73.5%)	50.7% (45.8%; 56.2%)	38.0% (33.0%; 43.6%)	28.4% (23.5%; 34.2%)	28.6% (23.6%; 34.7%)	19.5% (12.8%; 29.7%)
	IV	921	33.8% (30.8%; 37.1%)	16.2% (13.9%; 18.9%)	9.3% (7.4%; 11.6%)	6.9% (5.3%; 9.0%)	5.4% (3.9%; 7.5%)	4.5% (2.1%; 9.7%)
	X/NA	334	35.9% (30.8%; 41.9%)	20.9% (16.5%; 26.5%)	13.4% (9.5%; 18.8%)	8.7% (5.5%; 13.8%)	7.4% (4.3%; 12.5%)	7.0% (3.2%; 15.2%)
NENs	All	405	92.1% (89.2%; 95.0%)	90.4% (87.1%; 93.8%)	89.0% (85.3%; 92.9%)	88.7% (84.6%; 93.1%)	89.6% (85.2%; 94.3%)	86.8% (76.9%; 98.0%)
	I	218	97.7% (95.3%; 100.1%)	97.5% (94.4%; 100.8%)	99.1% (95.6%; 102.6%)	98.9% (94.6%; 103.5%)	102.3% (97.8%; 107.0%)	98.0% (79.8%; 120.3%)
	II	33	N<50	N<50	N<50	N<50	N<50	N<50
	III	15	N<50	N<50	N<50	N<50	N<50	N<50
	IV	21	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	118	92.8% (87.7%; 98.0%)	92.2% (86.6%; 98.1%)	86.7% (79.7%; 94.3%)	86.7% (79.2%; 95.0%)	84.3% (75.9%; 93.7%)	80.3% (67.8%; 95.2%)
Other	All	89	44.5% (34.6%; 57.1%)	38.2% (28.2%; 51.6%)	35.5% (25.2%; 50.1%)	32.4% (21.3%; 49.1%)	32.4% (21.3%; 49.1%)	FU<10y
	I	8	N<50	N<50	N<50	N<50	N<50	N<50
	II	12	N<50	N<50	N<50	N<50	N<50	N<50
	III	5	N<50	N<50	N<50	N<50	N<50	N<50
	IV	22	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	42	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Gastric cancer survival trends: by tumour stage

5.1.1. Gastric cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	3,416	50.8% (49.1%; 52.6%)	31.7% (30.0%; 33.5%)	28.5% (26.7%; 30.5%)	2,499	51.9% (49.8%; 54.0%)	35.4% (33.3%; 37.6%)	30.9% (28.7%; 33.4%)
	I	651	85.4% (82.3%; 88.6%)	76.8% (72.5%; 81.2%)	73.1% (68.0%; 78.5%)	498	84.2% (80.6%; 88.0%)	76.4% (71.5%; 81.6%)	71.0% (64.7%; 77.8%)
	II	357	82.9% (78.6%; 87.5%)	59.4% (53.6%; 65.8%)	52.7% (46.3%; 60.1%)	249	72.5% (66.8%; 78.7%)	53.8% (47.1%; 61.5%)	47.6% (40.5%; 55.9%)
	III	452	62.3% (57.7%; 67.2%)	30.2% (25.9%; 35.3%)	24.0% (19.7%; 29.2%)	277	57.3% (51.5%; 63.7%)	26.3% (21.2%; 32.6%)	19.4% (14.4%; 26.0%)
	IV	863	29.4% (26.4%; 32.7%)	5.9% (4.5%; 7.9%)	4.1% (2.9%; 6.0%)	543	28.9% (25.2%; 33.0%)	6.2% (4.4%; 8.6%)	3.3% (2.1%; 5.4%)
	X/NA	1,093	31.9% (29.1%; 34.9%)	16.6% (14.2%; 19.4%)	15.0% (12.6%; 17.9%)	932	40.8% (37.6%; 44.3%)	28.3% (25.1%; 31.8%)	24.5% (21.1%; 28.4%)
2010-2014	All	2,534	54.4% (52.3%; 56.4%)	32.8% (30.8%; 35.0%)	28.4% (26.3%; 30.6%)	1,890	55.0% (52.7%; 57.5%)	36.9% (34.5%; 39.4%)	32.8% (30.3%; 35.5%)
	I	434	82.0% (78.0%; 86.2%)	69.7% (64.2%; 75.6%)	70.1% (63.7%; 77.0%)	342	88.6% (84.7%; 92.7%)	76.8% (71.1%; 83.0%)	73.5% (67.0%; 80.7%)
	II	519	74.7% (70.8%; 78.9%)	50.7% (46.0%; 55.8%)	44.3% (39.3%; 50.0%)	341	74.2% (69.3%; 79.4%)	55.9% (50.0%; 62.4%)	48.7% (42.2%; 56.1%)
	III	425	63.0% (58.3%; 68.1%)	29.7% (25.3%; 35.0%)	19.1% (15.2%; 23.9%)	252	61.2% (55.3%; 67.8%)	32.3% (26.7%; 39.1%)	25.3% (19.9%; 32.0%)
	IV	631	27.6% (24.3%; 31.5%)	5.5% (3.9%; 7.7%)	2.8% (1.7%; 4.6%)	464	26.1% (22.3%; 30.5%)	5.9% (4.0%; 8.6%)	4.1% (2.5%; 6.6%)
	X/NA	525	36.1% (32.0%; 40.8%)	19.6% (16.0%; 23.9%)	15.7% (12.1%; 20.3%)	493	42.7% (38.2%; 47.6%)	27.7% (23.4%; 32.7%)	22.8% (18.6%; 28.0%)
2015-2019	All	2,201	56.9% (54.7%; 59.1%)	37.0% (34.8%; 39.4%)	32.4% (30.1%; 35.0%)	1,631	60.0% (57.6%; 62.6%)	39.9% (37.3%; 42.7%)	36.0% (33.2%; 38.9%)
	I	387	89.7% (86.0%; 93.6%)	82.1% (76.6%; 88.1%)	78.6% (71.7%; 86.2%)	322	90.9% (87.2%; 94.8%)	86.9% (81.6%; 92.7%)	85.3% (78.7%; 92.5%)
	II	414	72.7% (68.2%; 77.5%)	54.2% (48.8%; 60.1%)	47.9% (42.0%; 54.6%)	266	79.1% (73.9%; 84.6%)	55.6% (49.2%; 62.9%)	52.9% (45.9%; 61.0%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	354	68.6% (63.6%; 74.0%)	36.1% (31.0%; 42.1%)	26.1% (21.3%; 32.1%)	252	65.6% (59.7%; 72.0%)	30.5% (24.9%; 37.3%)	20.9% (15.9%; 27.5%)
	IV	724	31.4% (28.1%; 35.1%)	8.3% (6.4%; 10.9%)	5.2% (3.6%; 7.5%)	445	32.2% (28.0%; 36.9%)	9.5% (7.0%; 12.8%)	6.0% (4.0%; 8.9%)
	X/NA	325	41.4% (36.0%; 47.5%)	26.3% (21.4%; 32.5%)	23.8% (18.8%; 30.2%)	346	48.0% (42.7%; 54.0%)	29.2% (24.2%; 35.4%)	24.9% (19.9%; 31.1%)
2020-2024	**All**	1,939	61.4% (59.1%; 63.7%)	42.0% (39.4%; 44.7%)	35.2% (31.9%; 38.9%)	1,475	62.1% (59.6%; 64.8%)	43.3% (40.4%; 46.4%)	37.4% (33.9%; 41.2%)
	I	414	88.9% (85.3%; 92.6%)	80.8% (75.6%; 86.3%)	75.2% (66.1%; 85.7%)	374	89.7% (86.1%; 93.4%)	81.7% (76.2%; 87.7%)	77.5% (69.2%; 86.7%)
	II	338	76.7% (71.8%; 81.8%)	58.9% (52.6%; 65.8%)	52.0% (43.8%; 61.8%)	251	73.4% (67.8%; 79.5%)	50.5% (43.6%; 58.6%)	39.7% (31.7%; 49.8%)
	III	302	74.4% (69.3%; 80.0%)	52.6% (46.1%; 60.0%)	40.3% (32.6%; 49.8%)	186	72.1% (65.5%; 79.3%)	51.3% (43.4%; 60.6%)	43.6% (34.5%; 55.1%)
	IV	713	36.5% (33.0%; 40.3%)	10.2% (7.9%; 13.1%)	5.5% (3.5%; 8.8%)	519	34.4% (30.5%; 38.8%)	9.2% (6.8%; 12.5%)	5.4% (3.4%; 8.6%)
	X/NA	173	45.0% (37.8%; 53.7%)	26.3% (18.9%; 36.5%)	18.1% (10.4%; 31.3%)	148	58.3% (50.3%; 67.5%)	44.1% (35.2%; 55.2%)	38.6% (28.2%; 52.8%)

Note: Excluding gastrointestinal stromal tumours (GIST)

5.2. Gastric cancer survival trends: by tumour type and tumour stage

5.2.1. Gastric cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
GIST	**2004-2009**	All	322	96.8% (94.0%; 99.6%)	95.5% (90.9%; 100.3%)	97.9% (92.2%; 103.9%)	290	97.4% (94.9%; 100.0%)	94.9% (90.8%; 99.3%)	95.1% (90.0%; 100.5%)
	2010-2014	All	388	93.8% (90.8%; 96.9%)	92.4% (88.1%; 97.0%)	93.0% (87.4%; 98.9%)	409	95.4% (92.9%; 98.0%)	93.5% (89.8%; 97.3%)	95.3% (90.8%; 100.0%)
	2015-2019	All	525	96.1% (93.9%; 98.3%)	93.3% (89.9%; 96.8%)	93.3% (89.0%; 97.7%)	511	97.9% (96.1%; 99.8%)	95.8% (92.7%; 99.0%)	94.4% (90.0%; 99.1%)
	2020-2024	All	542	97.5% (95.5%; 99.4%)	90.2% (86.2%; 94.3%)	84.5% (77.1%; 92.6%)	552	98.1% (96.4%; 99.8%)	96.9% (94.1%; 99.8%)	97.0% (92.8%; 101.4%)
ADC	**2004-2009**	All	3,239	51.0% (49.3%; 52.9%)	31.4% (29.6%; 33.2%)	28.1% (26.3%; 30.1%)	2,297	49.8% (47.7%; 52.0%)	32.5% (30.4%; 34.8%)	28.0% (25.7%; 30.5%)
		I	627	85.1% (81.9%; 88.4%)	76.6% (72.3%; 81.1%)	73.3% (68.1%; 78.9%)	459	83.6% (79.8%; 87.6%)	75.8% (70.6%; 81.2%)	69.8% (63.2%; 77.1%)
		II	352	82.6% (78.3%; 87.3%)	59.6% (53.7%; 66.1%)	52.8% (46.3%; 60.2%)	243	73.1% (67.3%; 79.3%)	54.7% (47.9%; 62.5%)	48.3% (41.1%; 56.7%)
		III	445	62.8% (58.2%; 67.7%)	30.2% (25.8%; 35.4%)	24.1% (19.7%; 29.4%)	275	57.3% (51.5%; 63.8%)	26.1% (21.1%; 32.5%)	19.1% (14.2%; 25.8%)
		IV	822	30.2% (27.1%; 33.6%)	6.1% (4.6%; 8.1%)	4.4% (3.0%; 6.3%)	525	28.7% (25.0%; 32.9%)	5.8% (4.1%; 8.3%)	2.9% (1.7%; 4.9%)
		X/NA	993	30.3% (27.4%; 33.5%)	14.1% (11.8%; 16.9%)	12.1% (9.8%; 15.0%)	795	34.5% (31.2%; 38.2%)	20.6% (17.6%; 24.2%)	17.1% (14.0%; 21.1%)
	2010-2014	All	2,372	53.4% (51.3%; 55.5%)	31.2% (29.1%; 33.4%)	26.6% (24.5%; 28.9%)	1,676	53.0% (50.5%; 55.5%)	33.4% (30.9%; 36.0%)	29.4% (26.8%; 32.2%)
		I	402	81.7% (77.4%; 86.1%)	68.3% (62.5%; 74.5%)	68.6% (61.9%; 75.9%)	288	87.7% (83.3%; 92.4%)	75.0% (68.7%; 82.0%)	71.4% (64.2%; 79.4%)
		II	499	76.1% (72.1%; 80.3%)	51.4% (46.6%; 56.7%)	45.0% (39.9%; 50.8%)	327	74.9% (69.9%; 80.1%)	55.5% (49.6%; 62.2%)	49.5% (42.8%; 57.1%)
		III	415	63.1% (58.3%; 68.2%)	29.5% (25.0%; 34.8%)	19.0% (15.1%; 23.9%)	244	61.1% (55.1%; 67.9%)	31.6% (26.0%; 38.5%)	24.2% (18.9%; 31.1%)
		IV	608	26.8% (23.4%; 30.6%)	5.0% (3.4%; 7.1%)	2.2% (1.3%; 4.0%)	435	27.1% (23.2%; 31.7%)	6.3% (4.3%; 9.1%)	4.4% (2.7%; 7.0%)
		X/NA	448	29.5% (25.3%; 34.3%)	12.0% (8.9%; 16.0%)	8.0% (5.3%; 12.2%)	382	32.0% (27.4%; 37.5%)	14.8% (11.1%; 19.7%)	9.9% (6.6%; 14.9%)
	2015-2019	All	1,998	55.3% (53.0%; 57.7%)	34.4% (32.1%; 36.8%)	29.2% (26.8%; 31.8%)	1,400	56.1% (53.4%; 58.9%)	33.4% (30.7%; 36.3%)	28.7% (26.0%; 31.8%)
		I	336	88.7% (84.6%; 93.0%)	80.3% (74.1%; 86.9%)	75.6% (68.0%; 84.2%)	237	88.5% (83.7%; 93.5%)	82.9% (76.1%; 90.3%)	79.8% (71.5%; 89.1%)
		II	386	71.9% (67.2%; 76.9%)	53.0% (47.5%; 59.1%)	46.1% (40.0%; 53.1%)	246	78.0% (72.5%; 83.8%)	52.6% (45.9%; 60.2%)	49.6% (42.5%; 58.0%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	348	68.3% (63.3%; 73.8%)	35.5% (30.4%; 41.5%)	25.6% (20.7%; 31.6%)	243	65.9% (59.9%; 72.4%)	29.3% (23.7%; 36.2%)	19.3% (14.4%; 25.8%)
		IV	678	31.7% (28.3%; 35.5%)	8.4% (6.4%; 11.1%)	5.0% (3.4%; 7.4%)	429	32.4% (28.1%; 37.2%)	9.3% (6.8%; 12.7%)	5.6% (3.7%; 8.5%)
		X/NA	250	30.1% (24.6%; 36.9%)	12.1% (8.2%; 17.8%)	9.0% (5.6%; 14.5%)	245	34.1% (28.3%; 41.1%)	11.4% (7.5%; 17.3%)	6.0% (3.3%; 11.0%)
	2020-2024	All	1,695	58.9% (56.5%; 61.5%)	37.9% (35.3%; 40.7%)	31.0% (27.6%; 35.0%)	1,218	57.7% (54.9%; 60.7%)	35.7% (32.7%; 39.0%)	28.4% (24.9%; 32.5%)
		I	306	85.3% (80.8%; 90.1%)	76.1% (69.8%; 82.9%)	69.1% (58.2%; 82.0%)	235	85.6% (80.5%; 91.0%)	72.7% (65.1%; 81.3%)	63.1% (52.5%; 75.7%)
		II	302	77.2% (72.1%; 82.7%)	57.7% (51.1%; 65.1%)	50.8% (42.1%; 61.4%)	227	73.0% (67.1%; 79.5%)	48.5% (41.3%; 57.0%)	37.8% (29.6%; 48.4%)
		III	292	73.8% (68.5%; 79.5%)	51.9% (45.2%; 59.4%)	39.4% (31.6%; 49.1%)	175	72.6% (65.8%; 80.0%)	51.1% (43.1%; 60.7%)	43.4% (34.2%; 55.1%)
		IV	673	37.3% (33.7%; 41.2%)	10.1% (7.7%; 13.1%)	5.2% (3.2%; 8.7%)	492	35.0% (31.0%; 39.6%)	9.0% (6.6%; 12.4%)	5.1% (3.1%; 8.5%)
		X/NA	122	31.2% (23.5%; 41.3%)	10.2% (5.4%; 19.2%)	FU<5y	89	40.8% (31.1%; 53.4%)	19.4% (11.1%; 33.9%)	11.4% (4.2%; 30.5%)
NENs	**2004-2009**	All	93	60.8% (51.4%; 71.9%)	52.4% (42.5%; 64.8%)	49.5% (39.2%; 62.6%)	145	91.5% (86.6%; 96.7%)	86.1% (79.2%; 93.5%)	81.2% (72.9%; 90.4%)
		I	17	N<50	N<50	N<50	33	N<50	N<50	N<50
		II	4	N<50	N<50	N<50	2	N<50	N<50	N<50
		III	1	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	18	N<50	N<50	N<50	10	N<50	N<50	N<50
		X/NA	53	62.0% (50.0%; 77.0%)	58.9% (46.1%; 75.4%)	58.9% (46.1%; 75.4%)	98	92.5% (86.8%; 98.5%)	89.1% (81.8%; 97.1%)	83.0% (73.2%; 94.3%)
	2010-2014	All	113	79.0% (71.4%; 87.4%)	73.0% (64.1%; 83.1%)	69.1% (58.8%; 81.3%)	155	88.2% (82.8%; 94.0%)	84.6% (77.8%; 92.0%)	80.2% (72.1%; 89.2%)
		I	29	N<50	N<50	N<50	48	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	9	N<50	N<50	N<50
		III	7	N<50	N<50	N<50	6	N<50	N<50	N<50
		IV	15	N<50	N<50	N<50	7	N<50	N<50	N<50
		X/NA	51	88.2% (79.1%; 98.3%)	89.0% (77.6%; 102.1%)	86.7% (72.0%; 104.4%)	85	90.9% (84.5%; 97.9%)	87.5% (78.8%; 97.1%)	82.0% (72.4%; 92.8%)
	2015-2019	All	149	85.1% (79.1%; 91.5%)	76.4% (68.9%; 84.7%)	76.0% (67.9%; 85.2%)	188	92.8% (88.7%; 97.0%)	89.5% (84.2%; 95.1%)	89.0% (82.8%; 95.5%)
		I	46	N<50	N<50	N<50	84	98.4% (95.2%; 101.8%)	100.0% (95.2%; 105.0%)	99.5% (93.3%; 106.2%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	22	N<50	N<50	N<50	15	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	6	N<50	N<50	N<50
		IV	23	N<50	N<50	N<50	8	N<50	N<50	N<50
		X/NA	55	89.9% (81.2%; 99.6%)	85.0% (73.4%; 98.3%)	81.8% (68.2%; 98.1%)	75	93.4% (87.3%; 99.9%)	86.1% (77.3%; 95.8%)	81.8% (71.5%; 93.6%)
	2020-2024	All	177	92.1% (87.5%; 96.9%)	84.2% (77.2%; 91.8%)	80.1% (70.7%; 90.7%)	217	91.3% (87.3%; 95.4%)	88.6% (83.5%; 93.9%)	91.0% (85.2%; 97.3%)
		I	101	99.2% (95.7%; 102.9%)	94.1% (86.3%; 102.6%)	93.8% (83.4%; 105.5%)	134	97.1% (93.8%; 100.5%)	98.1% (93.6%; 102.7%)	102.0% (96.3%; 108.1%)
		II	25	N<50	N<50	N<50	18	N<50	N<50	N<50
		III	7	N<50	N<50	N<50	9	N<50	N<50	N<50
		IV	16	N<50	N<50	N<50	13	N<50	N<50	N<50
		X/NA	28	N<50	N<50	N<50	43	N<50	N<50	N<50
Other	**2004-2009**	All	84	30.9% (22.3%; 42.8%)	20.9% (13.6%; 32.3%)	19.0% (11.9%; 30.3%)	57	33.1% (22.8%; 48.2%)	20.0% (11.5%; 34.5%)	17.7% (8.9%; 35.0%)
		I	7	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	4	N<50	N<50	N<50
		III	6	N<50	N<50	N<50				
		IV	23	N<50	N<50	N<50	8	N<50	N<50	N<50
		X/NA	47	N<50	N<50	N<50	39	N<50	N<50	N<50
	2010-2014	All	51	46.7% (34.3%; 63.5%)	22.0% (12.3%; 39.3%)	19.2% (9.8%; 37.3%)	63	30.1% (20.5%; 44.2%)	15.3% (8.2%; 28.5%)	11.0% (5.2%; 23.2%)
		I	3	N<50	N<50	N<50	7	N<50	N<50	N<50
		II	9	N<50	N<50	N<50	5	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	8	N<50	N<50	N<50	22	N<50	N<50	N<50
		X/NA	27	N<50	N<50	N<50	27	N<50	N<50	N<50
	2015-2019	All	56	38.0% (26.9%; 53.8%)	26.2% (15.9%; 43.1%)	25.1% (15.0%; 42.1%)	44	N<50	N<50	N<50

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	5	N<50	N<50	N<50	2	N<50	N<50	N<50
		II	6	N<50	N<50	N<50	5	N<50	N<50	N<50
		III	2	N<50	N<50	N<50	3	N<50	N<50	N<50
		IV	23	N<50	N<50	N<50	8	N<50	N<50	N<50
		X/NA	20	N<50	N<50	N<50	26	N<50	N<50	N<50
	2020-2024	All	68	40.8% (30.3%; 54.9%)	31.6% (19.7%; 50.7%)	25.2% (13.3%; 47.7%)	45	N<50	N<50	N<50
		I	7	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	7	N<50	N<50	N<50
		III	3	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	24	N<50	N<50	N<50	14	N<50	N<50	N<50
		X/NA	23	N<50	N<50	N<50	16	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

6.1. Gastric cancer mortality: by region

6.1.1. Gastric cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	1	1	0	2	5	7	15	15	22	32	39	61	49	42	18	3	312	6.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.0]	[0.5]	[1.3]	[1.9]	[3.8]	[3.7]	[5.9]	[10.1]	[14.6]	[30.0]	[39.2]	[52.7]	[57.4]	[49.5]	[5.4]	(5.3; 6.6)
Brussels	0	0	0	0	0	0	0	0	0	1	2	1	1	2	3	2	3	2	1	0	18	4.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[4.9]	[2.8]	[3.5]	[9.4]	[17.8]	[15.8]	[37.3]	[40.0]	[43.4]	[0.0]	[3.0]	(2.5; 7.1)
Flanders	0	0	0	0	1	1	0	2	4	3	10	8	10	20	19	39	32	32	9	2	192	5.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.0]	[0.9]	[1.8]	[1.4]	[4.4]	[3.3]	[4.4]	[10.2]	[11.6]	[29.9]	[38.8]	[59.5]	[43.3]	[50.4]	[5.7]	(5.0; 6.6)
Wallonia	0	0	0	0	0	0	0	0	1	3	3	6	11	10	17	20	14	8	8	1	102	6.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.5]	[2.4]	[4.8]	[9.4]	[9.9]	[19.9]	[33.2]	[40.7]	[38.2]	[97.3]	[64.4]	[5.7]	(5.3; 8.0)
Females																						
Belgium	0	0	0	0	0	0	0	2	5	10	8	9	19	24	22	35	30	41	29	6	240	3.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.3]	[2.7]	[2.1]	[2.3]	[5.0]	[7.1]	[7.4]	[14.2]	[17.2]	[30.6]	[40.9]	[28.8]	[4.0]	(3.1; 4.0)
Brussels	0	0	0	0	0	0	0	1	2	3	0	3	4	2	0	4	3	4	1	0	27	5.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[4.4]	[7.3]	[0.0]	[8.8]	[13.2]	[8.0]	[0.0]	[22.2]	[23.4]	[40.8]	[17.6]	[0.0]	[4.3]	(3.1; 6.9)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	0	1	3	4	3	3	9	14	14	26	21	27	22	3	150	3.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.9]	[1.3]	[1.3]	[3.9]	[6.9]	[8.0]	[17.3]	[19.2]	[31.6]	[50.0]	[24.5]	[4.4]	(3.0; 4.1)
Wallonia	0	0	0	0	0	0	0	0	0	3	5	3	6	8	8	5	6	10	6	3	63	3.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.5]	[4.0]	[2.4]	[4.9]	[7.2]	[8.0]	[6.5]	[11.6]	[25.9]	[28.3]	[46.3]	[3.3]	(2.2; 3.7)

7.1. Gastric cancer mortality trends: by region

7.1.1. Gastric cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	464	463	465	447	438	416	380	445	434	397	394	418	372	352	335	344	369	343	322	312		
	CR	9.1	9.1	9.0	8.6	8.4	7.9	7.2	8.3	8.0	7.3	7.2	7.6	6.7	6.3	6.0	6.1	6.5	6.0	5.6	5.4		
	ESR2013	13.1	12.7	12.6	11.6	11.3	10.4	9.5	10.9	10.5	9.4	9.0	9.1	8.2	7.4	7.0	7.1	7.4	6.8	6.2	6.0	-4.0 (-4.4; -3.6)	2004-2023
Brussels	**N**	41	39	30	31	28	33	30	28	38	35	31	30	44	35	27	31	34	25	21	18		
	CR	8.5	8.1	6.1	6.2	5.5	6.4	5.7	5.2	6.9	6.2	5.5	5.2	7.6	6.0	4.6	5.2	5.7	4.2	3.5	3.0		
	ESR2013	13.2	11.1	9.0	9.8	8.3	9.3	8.5	8.3	12.0	10.1	8.8	8.7	11.5	9.2	7.4	8.4	8.6	7.1	5.6	4.8	-3.3 (-4.5; -2.1)	2004-2023
																						-0.7 (-2.5; 1.2)	2004-2017
																						-8.8 (-12.8; -4.6)	2018-2023
Flanders	**N**	308	286	300	278	291	274	255	292	284	258	254	275	227	228	224	226	246	228	206	192		
	CR	10.4	9.6	10.0	9.2	9.6	8.9	8.3	9.4	9.1	8.2	8.0	8.6	7.1	7.1	6.9	6.9	7.5	6.9	6.2	5.7		
	ESR2013	14.5	13.3	13.5	11.8	12.1	11.4	10.6	11.6	11.1	9.9	9.6	9.6	7.9	7.8	7.6	7.4	7.9	7.2	6.3	5.8	-4.3 (-4.8; -3.9)	2004-2023
Wallonia	**N**	115	138	135	138	119	109	95	125	112	104	109	113	101	89	84	87	89	90	95	102		
	CR	7.0	8.4	8.1	8.3	7.1	6.5	5.6	7.3	6.5	6.0	6.3	6.5	5.7	5.0	4.7	4.9	5.0	5.0	5.3	5.7		
	ESR2013	10.1	12.1	11.9	11.7	10.8	8.9	7.6	10.0	8.5	8.1	7.7	7.9	7.8	6.2	5.6	5.8	6.0	6.0	6.0	6.6	-3.9 (-4.7; -3.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Gastric cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	322	306	312	304	294	270	287	300	297	275	266	248	256	260	228	230	227	224	184	240		
	CR	6.1	5.7	5.8	5.6	5.4	4.9	5.2	5.4	5.3	4.9	4.7	4.3	4.5	4.5	3.9	4.0	3.9	3.8	3.1	4.0		
	ESR2013	6.0	5.7	5.7	5.4	5.1	4.7	4.9	5.0	4.8	4.3	4.1	3.9	3.9	4.0	3.4	3.4	3.3	3.4	2.7	3.5	-3.5 (-4.0; -3.0)	2004-2023
Brussels	**N**	26	19	15	26	24	30	17	35	18	25	35	23	15	22	20	23	17	18	27	27		
	CR	5.0	3.6	2.8	4.9	4.4	5.4	3.0	6.1	3.1	4.2	5.9	3.8	2.5	3.6	3.3	3.7	2.7	2.9	4.3	4.3		
	ESR2013	4.7	3.8	3.1	5.0	4.2	6.1	3.1	6.8	3.3	4.8	6.4	4.5	2.8	4.1	3.8	4.7	3.1	3.4	5.0	5.0	-0.3 (-2.4; 1.9)	2004-2023
Flanders	**N**	210	200	209	178	184	175	187	178	191	166	167	144	165	166	129	156	140	143	100	150		
	CR	6.9	6.5	6.8	5.7	5.9	5.6	5.9	5.6	5.9	5.1	5.1	4.4	5.0	5.0	3.9	4.7	4.2	4.3	3.0	4.4		
	ESR2013	6.9	6.5	6.6	5.4	5.6	5.2	5.4	5.0	5.2	4.5	4.4	3.8	4.2	4.3	3.2	3.8	3.3	3.5	2.4	3.5	-4.3 (-5.0; -3.5)	2004-2023
Wallonia	**N**	86	87	88	100	86	65	83	87	88	84	64	81	76	72	79	51	70	63	57	63		
	CR	4.9	5.0	5.0	5.7	4.8	3.6	4.6	4.8	4.8	4.6	3.5	4.4	4.1	3.9	4.3	2.7	3.8	3.4	3.0	3.3		
	ESR2013	4.9	5.0	4.8	5.6	4.6	3.6	4.4	4.6	4.4	4.0	3.1	3.9	3.7	3.5	3.7	2.3	3.4	3.1	2.7	3.0	-3.2 (-4.2; -2.3)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026